Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2017-03-01
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In HCC patients with incomplete TACE response, repeated TACE did not showed good response. In this case, SBRT could have better results than TACE.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SBRT (Stereotatic body radiotherapy)
Treatment of SBRT in HCC patients who have incomplete response after first TACE
SBRT
Maximum dose : 60Gray (Gy) Fraction : 2 to 5
TACE (Transarterial chemoembolization)
Treatment of repeated TACE in HCC patients who have incomplete response after first TACE
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SBRT
Maximum dose : 60Gray (Gy) Fraction : 2 to 5
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern cooperative oncology group(ECOG) score 0 to 2
* Primary HCC
* HCC (single nodule ≤ 7 cm or max 3 nodules ≤ 3 cm)
* Child-Turgottei-Pugh A or B
* Unresectable lesion or medically contraindicated surgery or a case in which surgery was declined.
* No evidence of radiologically definable major vascular invasion or extrahepatic disease
* Previously incomplete TACE with radiologically defined residual disease after first TACE
* Informed consent
Exclusion Criteria
* Contraindication to receiving radiotherapy or TACE
* Decompensated liver cirrhosis
* Extrahepatic mets
* Pregnancy
* Patients with other cancers
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Soonchunhyang University Hospital
OTHER
Gangneung Asan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gab Jin Cheon, M.D, Ph. D
Role: STUDY_DIRECTOR
University of Ulsan College of Medicine, Gangneung Asan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gangneung Asan Hospital
Wŏnju, Gangwondo, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Baek Gyu Jun, M.D
Role: primary
Gan Jin Cheon, M.D Ph.D.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GNH_RT-001
Identifier Type: -
Identifier Source: org_study_id